A new edition of Deals and Data, the monthly roundup of goings on in the world of San Diego biotech penned by Biocom’s Tim Ingersoll, is out this week.

Here are some highlights:

  • Sequenom, the San Diego-based maker of a prenatal test for Down syndrome, continues to make news. The company released the results of tests showing the test to have better than a 99 percent detection rate. The company’s stock was one of the few biotech success stories in 2008.
  • A drug discovered by Torrey Pines-based Ferring Research that treats advanced prostate cancer gained U.S. Food and Drug Administration approval.
  • Shares in San Diego-based Cypress Bioscience jumped 66 percent after the FDA approved its fibromyalgia treatment.
  • Carlsbad-based Isis Pharmaceuticals sold off its Ibis subsidiary to Abbot for $175 million.
  • La Jolla Pharmaceuticals entered into a partnership on its lupus drug with Bay Area-based BioMarin Pharmaceuticals.

Leave a comment

We expect all commenters to be constructive and civil. We reserve the right to delete comments without explanation. You are welcome to flag comments to us. You are welcome to submit an opinion piece for our editors to review.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.